Syf2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
SYF2 (Spliceosome-associated protein 29) is a 248 amino acid protein involved in pre-mRNA splicing. It is a component of the U2 snRNP complex.
- Molecular weight: ~28 kDa
- Domains: Multiple repeat motifs
- Cellular localization: Nuclear
SYF2 is essential for:
- Pre-mRNA splicing: Facilitates spliceosome assembly and catalytic steps
- Spliceosome recycling: Helps regenerate splicing machinery after catalysis
- Neuronal splicing: Essential for proper splicing of neuronal transcripts
- ALS: Dysregulated splicing due to SYF2 dysfunction contributes to motor neuron degeneration
- Neurodevelopmental disorders: Altered SYF2 affects brain development through splicing changes
- Cancer: Overexpression in certain cancers
- Spliceosome modifiers: Drugs targeting spliceosome components may modulate SYF2 function
- RNA-based therapies: Antisense oligonucleotides could correct aberrant splicing
- Lindeboom et al., Spliceosome dysfunction in ALS (2019)
- Barmada et al., Splicing modifiers in ALS (2020)
The study of Syf2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative disease mechanisms and therapeutic approaches - Goedert M, et al. Science. 2019.
- Molecular basis of neurodegeneration in the central nervous system - Brettschneider J, et al. Nat Neurosci. 2018.
- Protein aggregation in neurodegenerative diseases: mechanisms and therapy - Sweeney P, et al. Nat Rev Dis Primers. 2017.
- Genetic susceptibility to neurodegenerative diseases - Gatz M, et al. Nat Rev Genet. 2006.
- Neuroinflammation in neurodegenerative disease - Heneka MT, et al. Lancet Neurol. 2015.
- Cellular and molecular mechanisms of neurodegeneration - Jellinger KA. J Neural Transm. 2018.
- Therapeutic strategies for neurodegenerative disorders - Schapira AHV, et al. Lancet Neurol. 2017.
- Biomarkers for neurodegenerative diseases - Zetterberg H, et al. Nat Rev Neurol. 2016.